<p>NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY - 获取免费报告) 在周五交易前出现了跳空上涨。该股票之前收于 $2.95，但开盘价为 $3.10。NovaBay Pharmaceuticals 的股票最后交易价格为 $4.2880，成交量为 1,542,718 股。</p>
<h2>NovaBay Pharmaceuticals 股价上涨 84.6%</h2>
<p>该股票的 50 日移动平均线为 $1.37，200 日移动平均线为 $1.22。公司的市值为 6.8625 亿美元，市盈率为 -0.57，贝塔值为 0.57。</p>
<h2>NovaBay Pharmaceuticals 分红公告</h2>
<p>该公司最近宣布了一项分红，已于 9 月 29 日星期一支付。10 月 1 日星期三的登记股东获得了 $0.80 的分红。这代表了 3,791.0% 的分红收益率。该分红的除息日期为 9 月 30 日星期二。</p>
<h2>NovaBay Pharmaceuticals 的机构交易</h2>
<p>一些机构投资者和对冲基金最近买卖了 NBY 的股票。C2C Wealth Management LLC 在第二季度增持了 NovaBay Pharmaceuticals 的股份，增幅为 78.2%。C2C Wealth Management LLC 目前拥有 98,000 股该生物制药公司的股票，价值 $57,000，此前在上个季度又购买了 43,000 股。Apollon Wealth Management LLC 在第三季度购买了 NovaBay Pharmaceuticals 的新股份，价值约 $35,000。最后，Ground Swell Capital LLC 在第三季度购买了 NovaBay Pharmaceuticals 的新股份，价值约 $25,000。目前，23.25% 的股票由机构投资者持有。</p>
<h2>关于 NovaBay Pharmaceuticals</h2>
<p>(获取免费报告)</p>
<p>NovaBay Pharmaceuticals, Inc 是一家临床阶段的生物技术公司，专注于开发和商业化新型非抗生素抗感染产品，旨在调节先天免疫反应。利用其专有的 Aganocide® 技术，该公司的合成抗微生物化合物能够靶向并中和病原体，而不会导致抗生素耐药性。NovaBay 的研发工作集中在眼科、皮肤科和伤口护理应用上，旨在解决感染控制和炎症管理中的未满足需求。</p>
<p>该公司的主要商业产品包括 Avenova®，一种用于管理慢性睑板腺功能障碍和睑炎的眼睑和睫毛清洁溶液，以及 NeutroPhase®，一种用于急性和慢性伤口灌洗的纯次氯酸伤口和皮肤清洁剂。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 NovaBay Pharmaceuticals</li>
<li>3 只天然气股票，提供优厚的分红收益</li>
<li>人工智能热潮是泡沫吗？这两只分红股票说不是</li>
<li>最具波动性的股票，投资者需要了解的事项</li>
<li>2026 年的 4 只高潜力 ETF：小型股、太空股票等</li>
<li>内部人士卖出解释：这能否影响你的投资选择？</li>
<li>META 在科技下滑中上涨，特朗普的人工智能命令受到分析师赞扬</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 NovaBay Pharmaceuticals 吗？</h2>
<p>在考虑 NovaBay Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买... 而 NovaBay Pharmaceuticals 并不在名单上。</p>
<p>虽然 NovaBay Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

NovaBay制药

<p>NovaBay 制药（NYSEAMERICAN:NBY）股价飙升 84.6%，开盘价为 3.10 美元，最新交易价为 4.2880 美元。该公司宣布每股派息 0.80 美元，收益率达到 3,791.0%。机构投资者增加了持股。NovaBay 专注于非抗生素抗感染产品，主要产品包括 Avenova®和 NeutroPhase®。尽管近期股价大幅上涨，分析师目前对该股票的评级为持有</p>

<p>NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $2.95, but opened at $3.10. NovaBay Pharmaceuticals shares last traded at $4.2880, with a volume of 1,542,718 shares traded.</p>
<div class="lb-trans"><p>NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY - 获取免费报告) 在周五交易前出现了跳空上涨。该股票之前收于 $2.95，但开盘价为 $3.10。NovaBay Pharmaceuticals 的股票最后交易价格为 $4.2880，成交量为 1,542,718 股。</p>
</div><h2>NovaBay Pharmaceuticals Trading Up 84.6%</h2>
<div class="lb-trans"><h2>NovaBay Pharmaceuticals 股价上涨 84.6%</h2>
</div><p>The stock has a 50 day moving average of $1.37 and a 200-day moving average of $1.22. The company has a market capitalization of $686.25 million, a P/E ratio of -0.57 and a beta of 0.57.</p>
<div class="lb-trans"><p>该股票的 50 日移动平均线为 $1.37，200 日移动平均线为 $1.22。公司的市值为 6.8625 亿美元，市盈率为 -0.57，贝塔值为 0.57。</p>
</div><h2>NovaBay Pharmaceuticals Dividend Announcement</h2>
<div class="lb-trans"><h2>NovaBay Pharmaceuticals 分红公告</h2>
</div><p>The business also recently announced a dividend, which was paid on Monday, September 29th. Stockholders of record on Wednesday, October 1st were issued a $0.80 dividend. This represents a dividend yield of 3,791.0%. The ex-dividend date of this dividend was Tuesday, September 30th.</p>
<div class="lb-trans"><p>该公司最近宣布了一项分红，已于 9 月 29 日星期一支付。10 月 1 日星期三的登记股东获得了 $0.80 的分红。这代表了 3,791.0% 的分红收益率。该分红的除息日期为 9 月 30 日星期二。</p>
</div><h2>Institutional Trading of NovaBay Pharmaceuticals</h2>
<div class="lb-trans"><h2>NovaBay Pharmaceuticals 的机构交易</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of NBY. C2C Wealth Management LLC boosted its holdings in shares of NovaBay Pharmaceuticals by 78.2% during the 2nd quarter. C2C Wealth Management LLC now owns 98,000 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 43,000 shares during the last quarter. Apollon Wealth Management LLC bought a new stake in shares of NovaBay Pharmaceuticals in the third quarter worth about $35,000. Finally, Ground Swell Capital LLC purchased a new stake in shares of NovaBay Pharmaceuticals in the third quarter worth about $25,000. 23.25% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近买卖了 NBY 的股票。C2C Wealth Management LLC 在第二季度增持了 NovaBay Pharmaceuticals 的股份，增幅为 78.2%。C2C Wealth Management LLC 目前拥有 98,000 股该生物制药公司的股票，价值 $57,000，此前在上个季度又购买了 43,000 股。Apollon Wealth Management LLC 在第三季度购买了 NovaBay Pharmaceuticals 的新股份，价值约 $35,000。最后，Ground Swell Capital LLC 在第三季度购买了 NovaBay Pharmaceuticals 的新股份，价值约 $25,000。目前，23.25% 的股票由机构投资者持有。</p>
</div><h2>About NovaBay Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 NovaBay Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company's synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay's research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.</p>
<div class="lb-trans"><p>NovaBay Pharmaceuticals, Inc 是一家临床阶段的生物技术公司，专注于开发和商业化新型非抗生素抗感染产品，旨在调节先天免疫反应。利用其专有的 Aganocide® 技术，该公司的合成抗微生物化合物能够靶向并中和病原体，而不会导致抗生素耐药性。NovaBay 的研发工作集中在眼科、皮肤科和伤口护理应用上，旨在解决感染控制和炎症管理中的未满足需求。</p>
</div><p>The company's primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.</p>
<div class="lb-trans"><p>该公司的主要商业产品包括 Avenova®，一种用于管理慢性睑板腺功能障碍和睑炎的眼睑和睫毛清洁溶液，以及 NeutroPhase®，一种用于急性和慢性伤口灌洗的纯次氯酸伤口和皮肤清洁剂。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than NovaBay Pharmaceuticals</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>META Rises Amid Tech Decline, Trump's AI Order Praised By Analyst</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 NovaBay Pharmaceuticals</li>
<li>3 只天然气股票，提供优厚的分红收益</li>
<li>人工智能热潮是泡沫吗？这两只分红股票说不是</li>
<li>最具波动性的股票，投资者需要了解的事项</li>
<li>2026 年的 4 只高潜力 ETF：小型股、太空股票等</li>
<li>内部人士卖出解释：这能否影响你的投资选择？</li>
<li>META 在科技下滑中上涨，特朗普的人工智能命令受到分析师赞扬</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in NovaBay Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 NovaBay Pharmaceuticals 吗？</h2>
</div><p>Before you consider NovaBay Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 NovaBay Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NovaBay Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买... 而 NovaBay Pharmaceuticals 并不在名单上。</p>
</div><p>While NovaBay Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 NovaBay Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

NovaBay 制药（NYSEAMERICAN:NBY）股价跳空高开 - 现在是买入的好时机吗？